IL174525A0 - Medicamentously targeted local lipolysis - Google Patents

Medicamentously targeted local lipolysis

Info

Publication number
IL174525A0
IL174525A0 IL174525A IL17452506A IL174525A0 IL 174525 A0 IL174525 A0 IL 174525A0 IL 174525 A IL174525 A IL 174525A IL 17452506 A IL17452506 A IL 17452506A IL 174525 A0 IL174525 A0 IL 174525A0
Authority
IL
Israel
Prior art keywords
medicamentously
targeted local
local lipolysis
lipolysis
adipose tissue
Prior art date
Application number
IL174525A
Other languages
English (en)
Original Assignee
Merz Pharmaceuticals Gmbh
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34529797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL174525(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharmaceuticals Gmbh, Sanofi Aventis Deutschland filed Critical Merz Pharmaceuticals Gmbh
Publication of IL174525A0 publication Critical patent/IL174525A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL174525A 2003-10-24 2006-03-23 Medicamentously targeted local lipolysis IL174525A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10349979A DE10349979B4 (de) 2003-10-24 2003-10-24 Medikamentöse gezielte lokale Lipolyse
PCT/EP2004/011320 WO2005041919A2 (de) 2003-10-24 2004-10-09 Medikamentöse gezielte lokale lipolyse

Publications (1)

Publication Number Publication Date
IL174525A0 true IL174525A0 (en) 2006-08-01

Family

ID=34529797

Family Applications (1)

Application Number Title Priority Date Filing Date
IL174525A IL174525A0 (en) 2003-10-24 2006-03-23 Medicamentously targeted local lipolysis

Country Status (13)

Country Link
EP (1) EP1684722B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007509085A (cg-RX-API-DMAC7.html)
KR (1) KR20060117914A (cg-RX-API-DMAC7.html)
CN (1) CN100482211C (cg-RX-API-DMAC7.html)
AT (1) ATE418965T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004285264A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415756A (cg-RX-API-DMAC7.html)
CA (1) CA2543187A1 (cg-RX-API-DMAC7.html)
DE (2) DE10349979B4 (cg-RX-API-DMAC7.html)
ES (1) ES2319997T3 (cg-RX-API-DMAC7.html)
IL (1) IL174525A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004081A (cg-RX-API-DMAC7.html)
WO (1) WO2005041919A2 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10361067A1 (de) * 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medikamentöse Lipolyse von Fettansammlungen
ES2372499T3 (es) * 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
DE102007015701A1 (de) 2007-03-19 2008-09-25 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue pharmazeutische Zusammensetzungen für die Lipolyse und Verfahren zu deren Herstellung
CN102481305B (zh) 2009-08-25 2015-08-19 美德阿利克斯株式会社 磷脂酰胆碱的经皮组合物及其制备方法
DE102010028365A1 (de) * 2010-04-29 2011-11-03 Lichtblick Gmbh Verwendung einer Phospholipid enthaltenden Zusammensetzung zur Entfernung von subkutanen Fettansammlungen
KR101353443B1 (ko) * 2012-02-07 2014-01-29 주식회사 아미팜 데옥시콜린산 나트륨이 없는 포스파티딜콜린 함유 주사제 조성물 및 이의 제조방법
BR112014029188B1 (pt) * 2012-05-31 2020-02-11 Terumo Kabushiki Kaisha Veículo sensível ao ph e método de preparação do mesmo, e droga sensível ao ph e composição medicamentosa sensível ao ph contendo o veículo, e método de cultura usando o mesmo
BR112016030341A8 (pt) * 2014-06-27 2021-07-20 Medytox Inc formulação para a remoção não cirúrgica de um depósito de gordura localizada em um indivíduo, método para a remoção não cirúrgica de depósitos de gordura localizada em um indivíduo que tem acúmulo de gordura localizada, e kit
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
US12616651B2 (en) 2014-11-21 2026-05-05 Lipodissolve Therapeutics Inc. Topical lipolysis composition and methods
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
EP3479827B1 (en) 2017-04-21 2023-05-10 AMI Pharm Co., Ltd. Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same
KR101865562B1 (ko) * 2017-11-03 2018-06-08 주식회사 펜믹스 포스포콜린 유도체를 포함하는 지방분해 조성물
WO2019150594A1 (ja) 2018-01-31 2019-08-08 株式会社ユニッシュ ホスファチジルコリン経皮吸収製剤
KR20190095833A (ko) * 2018-02-07 2019-08-16 이기택 고통 및 부작용이 없는 국소지방 감소용 포스파티딜콜린 비포함 주사제 조성물
WO2019203543A1 (ko) * 2018-04-18 2019-10-24 (주)인벤티지랩 데옥시콜린산을 포함하는 피하 주사용 조성물 및 이의 제조 방법
KR102939043B1 (ko) 2020-06-01 2026-03-16 코스메드 파마소티컬 씨오 쩜 엘티디 미용용 마이크로니들 어레이
CN116889548B (zh) * 2022-03-31 2026-07-21 四川汇宇制药股份有限公司 一种脂质体递药系统及其制备方法和用途
KR20260079596A (ko) 2023-09-27 2026-06-02 쓰추안 휘위 파머슈티컬 컴퍼니., 리미티드. 리포좀 약물 전달 시스템 및 이의 제조 방법, 리포좀 제제, 용도, 이를 포함한 체지방 감소 약물 또는 의료 미용 제품

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2556592C2 (de) * 1975-12-16 1986-10-09 A. Nattermann & Cie GmbH, 5000 Köln Arzneimittelzubereitungen auf Basis öliger Lösungen von Phospholipiden
DE4122744C2 (de) * 1990-08-06 1994-02-03 Nattermann A & Cie Wäßriges Liposomensystem und Verfahren zu seiner Herstellung
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
DE4308121A1 (de) 1993-03-15 1994-09-22 Rhone Poulenc Rorer Gmbh Wäßriges Liposomensystem sowie Verfahren zur Herstellung eines derartigen Liposomensystems
ITMI20011182A1 (it) * 2001-06-05 2002-12-05 Indena Spa Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite

Also Published As

Publication number Publication date
CN100482211C (zh) 2009-04-29
KR20060117914A (ko) 2006-11-17
HK1096857A1 (zh) 2007-06-15
CN1870977A (zh) 2006-11-29
ATE418965T1 (de) 2009-01-15
WO2005041919A3 (de) 2005-06-23
DE502004008793D1 (cg-RX-API-DMAC7.html) 2009-02-12
EP1684722B1 (de) 2008-12-31
JP2007509085A (ja) 2007-04-12
EP1684722A2 (de) 2006-08-02
DE10349979B4 (de) 2006-05-18
BRPI0415756A (pt) 2006-12-19
WO2005041919A2 (de) 2005-05-12
ES2319997T3 (es) 2009-05-18
CA2543187A1 (en) 2005-05-12
MXPA06004081A (es) 2006-06-27
DE10349979A1 (de) 2005-06-16
AU2004285264A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
WO2005041919A3 (de) Medikamentöse gezielte lokale lipolyse
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
TW201712023A (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
EP1809280A4 (en) MITOTIC KINESINE INHIBITORS AND METHOD OF USE THEREOF
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
DE50310516D1 (de) Fredericamycin-derivate
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
EA201891507A1 (ru) Кислая альфа-глюкозидаза усиленного действия для лечения болезни помпе
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
WO2019102380A8 (en) Therapeutic treatment of breast cancer based on c-maf status
EA200970154A1 (ru) Косметические или дерматологические препараты, содержащие n-ацетилцистеин
TW200611695A (en) Pyrrolopyridine derivatives
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
CY1116938T1 (el) Αναπληρωτικη θεραπεια της ασθενειας huntington και αλλων ασθενειων πολυγλουταμiνης
CY1111353T1 (el) Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης
MXPA05003818A (es) Perfilamiento de la expresion genica de muestras ffpe.
WO2010031708A3 (en) Ortho-aminoanilides for the treatment of cancer
MX2009005550A (es) Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica.
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
JP2009535298A5 (cg-RX-API-DMAC7.html)
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen